AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S. market
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Abbvie (ABBV) Humira guidance removes overhang - Truist
February 9, 2023 1:39 PM ESTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV) as Humira guidance removes overhang.
The analyst commented, "Following ABBV's 4Q2022 earnings call, we are reiterating our Buy rating as 1) we believe that the guidance provided... More
AbbVie (ABBV) shares rise on earnings beat - prepared for loss of Humira exclusivity
February 9, 2023 10:00 AM ESTAbbVie (NYSE: ABBV) shares are up more than 3% in early Thursday trading after the company topped earnings estimates for the fourth quarter.
Earnings came in at $3.60 per share, $0.07 better than the analyst estimate of $3.53. However, the biotech firm missed the analyst consensus revenue forecast of $15.33 billion, coming in at $15.12 billion.
The company's results included an unfavorable impact of $0.13 per share related to the fourth-quarter 2022 acquired IPR&D and milestones expense.
The... More
